Hennrich Ute, Wagner Laurène, Taş Harun, Kovacs Luciana, Benešová-Schäfer Martina
Service Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Pharmaceuticals (Basel). 2025 Jun 17;18(6):906. doi: 10.3390/ph18060906.
Locametz/Illuccix/Gozellix (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [Ga]Ga-PSMA-11), Pylarify/Pylclari (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [F]DCFPyL), Radelumin (ABX GmbH (Radeberg, Germany), [F]PSMA-1007), and Posluma (Blue Earth Diagnostics, Ltd. (Oxford, UK), [F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.
Locametz/Illuccix/Gozellix（诺华公司（瑞士巴塞尔）和特利克斯制药有限公司（澳大利亚墨尔本），均为[镓]镓-PSMA-11）、Pylarify/Pylclari（普洛吉尼克斯制药公司（美国纽约）和法国居里PET公司（法国巴黎），均为[氟]DCFPyL）、Radelumin（ABX股份有限公司（德国拉德贝格），[氟]PSMA-1007）以及Posluma（蓝地球诊断有限公司（英国牛津），[氟]重组人PSMA-7.3）是四种已获批的PSMA-PET成像剂，它们极大地推动了前列腺癌的诊断和治疗。这些药剂提供了新的精准度和准确性水平，使临床医生能够以更高灵敏度检测前列腺癌。因此，它们在改善检测、分期和治疗方面发挥着关键作用，最终提高患者的临床治疗效果。它们在常规临床实践中的应用有望提高诊断精度，并为个性化治疗提供更清晰的途径。本综述提供了全面的化学、药学和医学概述，讨论了对比研究，并重点介绍了其他与前列腺癌检测高度相关的候选药剂。
